Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

KENILWORTH, N.J. & DALLAS–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada,
and Peloton Therapeutics, Inc. today announced that the companies have
entered into a definitive agreement under which Merck, through a
subsidiary, will acquire privately held Peloton, a clinical-stage
biopharmaceutical company focused on the development of novel small
molecule therapeutic candidates targeting hypoxia-inducible factor-2α
(HIF-2α) for the treatment of patients with cancer and other
non-oncology diseases.

read more

Read Original Article: Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline »